Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

September 21, 2019 | APPEARED IN VOLUME 97, ISSUE 37


Entegris has purchased Hangzhou Anow Microfiltration, a Chinese maker of filtration products, for $76 million. Anow brings Entegris polymeric membrane technologies for industries including semiconductors and drug manufacturing, Entegris says.

Orbia is the new name of Mexichem, a Mexican maker of polyvinyl chloride, fluorinated chemicals, and other products. Orbia employs more than 22,000 people and had sales of $7.2 billion last year.

CP Kelco will expand production of low-methoxyl amidated (LMA) pectin by 15% at its plant in Lille Skensved, Denmark, to meet rising global demand. LMA pectin, made from citrus peels, is used as an emulsifier and thickener in yogurt drinks and fruit products.

Lygos, a California start-up commercializing biobased malonic acid, says it received $5 million from South Korea’s CJ CheilJedang in its second funding round in late 2018. The start-up says it will benefit from CJ’s global footprint and manufacturing and logistics know-how.

SK Holdings has formed the contract manufacturer SK Pharmteco by combining SK Biotek in South Korea, SK Biotek in Ireland, and Ampac Fine Chemicals in California. Former Ampac CEO Aslam Malik will lead the US-based business.

Albemarle has completed an operations building at its Tyrone, Pennsylvania, fine chemical custom manufacturing facility. The building includes new labs with inductively coupled plasma mass spectrometry for elemental metal impurity analysis.

Unnatural Products, a start-up combining artificial intelligence and chemistry, has raised more than $6 million in seed funding. The California-based firm is developing macrocyclic oncology drugs.

Atomwise, a developer of artificial intelligence for drug discovery, has signed R&D pacts with four firms: China’s Jiangsu Hansoh Pharmaceutical, Ohio-based OncoStatyx, Seattle’s SEngine Precision Medicine, and California’s Atropos Therapeutics.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment